Table 10 Frequency and percentage of group with COPD Risk as assessed by LFQ Scores
From: Effects of Chinese medicine for COVID-19 rehabilitation: a multicenter observational study
| Â | Participants with particular CM syndromes | Participants without particular CM syndromes | ||||
|---|---|---|---|---|---|---|
| Â | N | At risk | No risk | N | At risk | No risk |
V1 | 107 | 24 | 84 | 42 | 5 | 37 |
| Â | Â | 22.22% | 77.78% | Â | 11.9% | 88.1% |
V2 | 99 | 11 | 88 | 46 | 4 | 42 |
| Â | Â | 11.11% | 88.89% | Â | 8.7% | 91.3% |
V3 | 86 | 14 | 78 | 43 | 1 | 42 |
| Â | Â | 15.22% | 84.78% | Â | 2.33% | 97.67% |
V4 | 86 | 13 | 78 | 47 | 4 | 43 |
| Â | Â | 14.29% | 85.71% | Â | 8.51% | 91.49% |
V5 | 81 | 15 | 68 | 46 | 4 | 42 |
| Â | Â | 18.07% | 81.93% | Â | 8.7% | 91.3% |
V6 | 72 | 9 | 66 | 43 | 3 | 40 |
| Â | Â | 12% | 88% | Â | 6.98% | 93.02% |
V7 | 67 | 9 | 64 | 44 | 5 | 39 |
| Â | Â | 12.33% | 87.67% | Â | 11.36% | 88.64% |
V8 | 50 | 6 | 53 | 55 | 6 | 49 |
| Â | Â | 10.17% | 89.83% | Â | 10.91% | 89.09% |